Background
==========

A panel of sixty cancer cell lines of diverse lineage (lung, renal, colorectal, ovarian, breast, prostate, central nervous system, melanoma and hematological malignancies) was developed, characterized and extensively used by the National Cancer Institute\'s Developmental Therapeutics Program (NCI-60) since the early 90\'s as a screening tool for anti-cancer drug development \[[@B1]\]. This strategy \[[@B2]-[@B9]\]. yielded data about drug-related cytotoxicity for about 100,000 compounds. In addition, extensive functional characterization of the NCI-60 response to diverse biological or chemical stimulation has been accumulated \[[@B10]-[@B15]\]. Although originally developed for chemo-sensitivity testing, with the development of high-throughput analyses the NCI-60 panel has been broadly characterized for other biological applications \[[@B16]-[@B25]\]. Thus, patterns incidentally identified provided platforms for further investigations of mechanisms of tumorigenesis and cancer progression \[[@B5],[@B6],[@B26]-[@B30]\]. More recently, genomic DNA \[[@B24]\] and proteomics analyses have further characterized the profile of these cell lines \[[@B31]\]. The combined database provides the most comprehensive phenotyping of commonly accessible cancer cell lines offering correlative information about genetic, transcriptional and post-translational qualities. With growing interest in the identification of novel tumor antigens recognized by T cells as targets for antigen-specific immunization (\[[@B32]\], the NCI-60 could become an ideal tool for *in silico*discovery \[[@B33]\] (\[[@B34]\] and for tumor cell-specific T-cell reactivity testing \[[@B35]\]. For this purpose, accurate information about the extended human leukocyte antigen (HLA) phenotype of each cell line is necessary for the definition and validation of specific HLA/epitope combinations. Although antiquated and partial information about the HLA phenotype of some of the NCI-60 cell lines is available through the American Type Culture Collection (ATCC), Rockville, MD, no high-resolution information obtained by definitive sequence-based typing (SBT) has ever been published. Since T cell recognition of HLA-epitope complexes is narrowly restricted to unique combinations \[[@B36]\], this information is critical to select reasonable candidates for antigen-discovery choosing cell lines bearing HLA phenotypes most relevant to the disease population studied \[[@B37]\]. Accurate information about the HLA genotype of each cell line may, in addition, help their identification, validation and qualification among different laboratories excluding possible errors related to switching of cell lines or culture contamination. Therefore, we provide high-resolution SBT of the complete NCI-60 panel obtained from their original source: the National Cancer Institute\'s Developmental Therapeutics Program.

Results and Discussion
======================

Previous knowledge of the HLA phenotype of NCI-60 cell lines
------------------------------------------------------------

We reviewed and collected available information about the HLA phenotype of the NCI-60 cell lines, performed according to serological testing before submission to the ATCC (Table [1](#T1){ref-type="table"}). The information was collected through the ATCC website: <http://www.atcc.org>. Most cell lines had not been previously typed; the large majority of the cell lines from which such information is available had been developed from Caucasian patients. HLA typing was reported according to the old serologic nomenclature at a very low level of resolution. In addition, several reported typings did not match the present typing as shown in Table [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}. This was the case for the colon carcinoma cell line HT29 that maintained a correct haplotype (with the exclusion of the HLA-Cw locus) but had a completely different second haplotype. The melanoma cell line SK-MEL-5 had an almost identical haplotype with the exception of one HLA-B allele originally typed as Bw16 (inclusive of the molecularly-defined alleles: B\*38 and B\*39), while the present typing was HLA-B\*07. Another melanoma cell line SK-MEL-28 maintained a haplotype similar to the previously reported HLA-A11, -B40 but appeared to have lost an HLA-A allele (HLA-A26) compared with the original ATCC description. Finally, the multiple myeloma cell line RPMI 8226 was matched at one haplotype (HLA-A19, -B15 and -Cw2) but was totally discrepant at the second haplotype (HLA-A\*6802, -B\*1510 and -Cw\*0304). The HLA typing of the other two previously typed cell lines was confirmed in the present study. Overall, in spite of the discrepancies in HLA typing observed between the previous and the present analyses, a resemblance was noted in the cell line genotype suggesting that mis-typing related to the low accuracy of serological methods might have been at the basis of the discrepancy rather than contamination or switching of the cell lines.

###### 

Available information from the ATCC about the NCI-60 panel

  Name          ATCC no.   Sex   Race   Tumor Type       ATCC HLA typing         Discrepant
  ------------- ---------- ----- ------ ---------------- ----------------------- ------------
  BT-549        HTB-122    F     C      Breast CA                                
  HS 578T       HTB-126    F     C      Breast CA                                
  MCF7          HTB-22     F     C      Breast CA                                
  MDA-MB-231    HTB-26     F     C      Breast CA                                
  MDA-MB-435    HTB-129    F     C      Breast CA                                
  T-47D         HTB-133    F            Breast CA                                
  SF-268                                CNS CA                                   
  SF-295                                CNS CA                                   
  SF-539                                CNS CA                                   
  SNB-19                                CNS CA                                   
  SNB-75                                CNS CA                                   
  U251                                  CNS CA                                   
  COLO 205      CCL-222    M     C      Colon CA                                 
  HCC-2998                              Colon CA                                 
  HCT-116       CCL-247    M            Colon CA                                 
  HCT-15        CCL-225    M            Colon CA                                 
  HT29          HTB-38     F     C      Colon CA         **A1,3,B12,17 Cw5**     **Yes**
  KM12                                  Colon CA                                 
  SW-620        CCL-227    M            Colon CA                                 
  MOLT-4        CRL-1582   M            Leukemia, ALL                            
  CCRF-CEM      CCL-119    F     C      Leukemia, ALL                            
  HL-60         CCL-240    F     C      Leukemia, APL                            
  K-562         CCL-243    F            Leukemia, CML                            
  SR            CRL-2262   M     C      Leukemia, LCIL                           
  LOX IMVI                              Melanoma                                 
  M 14                                  Melanoma                                 
  SK-MEL-2      HTB-68     M     C      Melanoma                                 
  SK-MEL-5      HTB-70     F     C      Melanoma         **A2,11, B40,Bw16**     **Yes**
  SK-MEL-28     HTB-72     M            Melanoma         **A11,26, B40,DRw4**    **Yes**
  UACC-62                               Melanoma                                 
  UACC-257                              Melanoma                                 
  RPMI 8226     CCL-155    M            MM               **Aw19, B15,37, Cw2**   **Yes**
  A549/ATCC     CCL-185    M     C      NSCLC                                    
  EKVX                                  NSCLC                                    
  HOP-62                                NSCLC                                    
  HOP-92                                NSCLC                                    
  NCI-H23       CRL-5800   M     AA     NSCLC                                    
  NCI-H226      CRL-5826   M            NSCLC                                    
  NCI-H322M                             NSCLC                                    
  NCI-H460      HTB-177    M            NSCLC                                    
  NCI-H522      CRL-5810   M     C      NSCLC                                    
  IGROV1                                Ovarian CA                               
  OVCAR-3       HTB-161                 Ovarian CA                               
  OVCAR-4                               Ovarian CA                               
  OVCAR-5                               Ovarian CA                               
  OVCAR-8                               Ovarian CA                               
  NCI/ADR-RES                           Ovarian CA                               
  SK-OV-3       HTB-77     F     C      Ovarian CA                               
  DU-145        HTB-81     M     C      Prostate CA                              
  PC-3          CRL-1435   M     C      Prostate CA      **A1,9**                **No**
  786-O                                 Renal CA                                 
  A498          HTB-44     F            Renal CA                                 
  ACHN          CRL-1611   M     C      Renal CA                                 
  CAK1-1        HTB-46     M     C      Renal CA         **A9,B12,35**           **No**
  SN12C                                 Renal CA                                 
  TK-10                                 Renal CA                                 
  UO-31                                 Renal CA                                 
  RXF-393                               Renal CA                                 

AA = African American; ALL = Acute Lymphoblastic Leukemia; APL = Acute promyelocytic leukemia; C = Caucasian; CA = Carcinoma; CML = Chronic Myelogenous Leukemia; CNS = Central Nervous System; F = Female; LCIL = Large Cell Immunoblastic Lymphoma; M = Male; MM = Multiple Myeloma; NA = Not Available; NSCLC = Non Small Cell Lung Cancer.

The information about the ATCC cell lines (Cell Lines with ATCC no.) was obtained accessing the following URL: <http://www.atcc.org>. Additional information was obtained through the National Cancer Institute\'s Developmental Therapeutics Program URL: <http://dtp.nci.nih.gov/branches/btb/tumor-catalog.pdf>.

###### 

Sequence-based typing of NCI-60 HLA class I Loci

  Cell Line     ID        Tissue           A locus          B Locus          Cw Locus
  ------------- --------- ---------------- ---------------- ---------------- ----------------
  BT-549        41292-D   Breast CA        N.R.             151701, 5501     030301, 07^a^
  HS 578T       41293-D   Breast CA        03^a^, 24^a^     35^a^, 40^a^     030401, 04^a^
  MCF7          41294-D   Breast CA        020101           18^a^, 44^a^     05^a^
  MDA-MB-231    41296-D   Breast CA        0201, 0217       4002, 4101       020202, 17^a^
  MDA-MB435     41297-D   Breast CA        110101, 240201   15^a^, 35^a^     030301, 04^a^
  T47D          41298-D   Breast CA        3301             1402             0802
  SF-268        41286-D   CNS CA           010101, 3201     0801, 4002       020202, 07^a^
  SF-295        41287-D   CNS CA           010101, 2601     070201, 5501     03^a^, 07^a^
  SF-539        41288-D   CNS CA           020101           08^a^, 35^a^     04^a^, 07^a^
  SNB-19        41289-D   CNS CA           020101           18^a^            05^a^
  SNB-75        41290-D   CNS CA           020101, 110101   35^a^, 39^a^     04^a^, 120301
  U251          41291-D   CNS CA           020101           18^a^            05^a^
  COLO 205      41299-D   Colon CA         01^a^, 02^a^     07^a^, 08^a^     070201, 07^a^
  HCC-2998      41300-D   Colon CA         02^a^, 24^a^     3701, 400601     04^a^, 0602
  HCT-116       41301-D   Colon CA         01^a^, 02^a^     18^a^, 4501      05^a^, 07^a^
  HCT-15        41302-D   Colon CA         02^a^, 24^a^     08new, 350101    04^a^, 07^a^
  HT29          41303-D   Colon CA         01^a^, 24^a^     35^a^, 440301    04^a^
  KM12          41304-D   Colon CA         02new            70201            70201
  SW-620        41305-D   Colon CA         02^a^, 24^a^     07^a^, 15^a^     070201, 07^a^
  MOLT 4        41281-D   Leukemia, ALL    010101, 2501     18^a^, 570101    0602, 120301
  CCRF-CEM      41282-D   Leukemia, ALL    N.R.             08^a^, 40^a^     030401, 07^a^
  HL-60         41284-D   Leukemia, APL    10101            570101           0602
  K-562         41280-D   Leukemia, CML    110101, 310102   18^a^, 40^a^     03^a^, N.R.
  SR            41285-D   Leukemia, LCIL   02^a^, 03^a^     3701, 3901       0602, 120301
  LOX IMVI      41315-D   Melanoma         110101, 2902     070201, 440301   070201, 1601
  M 14          41316-D   Melanoma         110101, 240201   15^a^, 35^a^     030301, 04^a^
  SK-MEL-2      41317-D   Melanoma         03^a^, 26^a^     35^a^, 38^a^     04^a^, 120301
  SK-MEL-5      41319-D   Melanoma         020101, 110101   07^a^, 40^a^     030401, 070201
  SK-MEL-28     41318-D   Melanoma         110101           4001             030401
  UACC-62       41321-D   Melanoma         02^a^, 32^a^     39^a^, 44^a^     05^a^, 12^a^
  UACC-257      41320-D   Melanoma         020101           18^a^, 44^a^     05^a^, 07^a^
  RPMI-8226     41283-D   MM               3001, 6802       1503, 1510       020204, 030402
  A549/ATCC     41306-D   NSCLC            2501, 3001       18^a^, 440301    120301, 1601
  EKVX          41307-D   NSCLC            010101           3701             0602
  HOP-62        41308-D   NSCLC            030101           07^a^, 44^a^     05^a^, 070201
  HOP-92        41309-D   NSCLC            03^a^, 24^a^     27^a^, 470101    01^a^, 06^a^
  NCI-H23       41312-D   NSCLC            8001             5001             0602
  NCI-H226      41311-D   NSCLC            010101, 240201   07^a^, 39^a^     070201, 120301
  NCI-H322M     41310-D   NSCLC            2902             440301           1601
  NCI-H460      41313-D   NSCLC            24^a^, 68^a^     35^a^, 51^a^     03^a^, 15^a^
  NCI-H522      41314-D   NSCLC            020101           44^a^, 5501      030301, 05^a^
  IGROV1        41322-D   Ovarian CA       240201, 3301     4901             07^a^
  OVCAR-3       41323-D   Ovarian CA       020101, 2902     070201, 5801     070201, 07^a^
  OVCAR-4       41324-D   Ovarian CA       010101, 3201     0801, 4002       07^a^, 15^a^
  OVCAR-5       41325-D   Ovarian CA       01^a^, 02^a^     08^a^, 44^a^     05^a^, 07^a^
  OVCAR-8       41326-D   Ovarian CA       010101, 2501     570101           0602
  NCI/ADR-RES   41295-D   Ovarian CA       010101, 2501     570101           0602
  SK-OV-3       41327-D   Ovarian CA       03^a^, 68^a^     18^a^, 35^a^     04^a^, 05^a^
  DU-145        41328-D   Prostate CA      030101, 3303     5001, 570101     0602
  PC-3          41329-D   Prostate CA      010101, 240201   1302, 5501       01^a^, 06^a^
  786-O         41330-D   Renal CA         030101           07^a^, 44^a^     05^a^, 070201
  A498          41331-D   Renal CA         020101           0801             07^a^
  ACHN          41332-D   Renal CA         2601             4901             07^a^
  CAKI-1        41333-D   Renal CA         2301, 240201     3502, 440301     04^a^, 04new
  SN12C         41334-D   Renal CA         03, 24new        07^a^, 44^a^     05^a^, 070201
  TK-10         41335-D   Renal CA         3301             1402             0802
  UO-31         41336-D   Renal CA         010101, 030101   07^a^, 14^a^     07^a^, 08^a^
  RXF-393       41337-D   Renal CA         02^a^, 24^a^     1401, 44^a^      05^a^, 0802

Sequence-based typing for the HLA class I loci are reported with the highest degree of resolution. Non-resolved ambiguities are reported as two digit denominations with a superscript ^a^as previously described 43. HLA typings divergent from those originally described in the ATCC database are reported in red. ID\# refers to the HLA laboratory reference number. New alleles are indicated by the suffix new following the allele. N.R. -- Ambiguity not resolved at the lower level of resolution.

###### 

Sequence-based typing of NCI-60 HLA class II Loci

  Cell Line     ID        Tissue           DRβ1 Locus       DQB1 Locus       DPB1 Locus
  ------------- --------- ---------------- ---------------- ---------------- --------------
  BT-549        41292-D   Breast CA        11^a^, 13^a^     030101, 060401   020102, 0401
  HS 578T       41293-D   Breast CA        01^a^, 150101    050101, 0602     0401, 7801
  MCF7          41294-D   Breast CA        03^a^, 15^a^     0201, 0602       020102, 0401
  MDA-MB-231    41296-D   Breast CA        0701, 1305       0202, 030101     020102, 1701
  MDA-MB435     41297-D   Breast CA        040501, 130101   0302, 0603       1301, 1901
  T47D          41298-D   Breast CA        010201           050101           020102, 0401
  SF-268        41286-D   CNS CA           03^a^, 04^a^     0201, 0302       0401, 0601
  SF-295        41287-D   CNS CA           14^a^, 15^a^     050301, 0602     0401
  SF-539        41288-D   CNS CA           030101, 12^a^    0201, 030101     010101, 0401
  SNB-19        41289-D   CNS CA           030101           0201             0402
  SNB-75        41290-D   CNS CA           0103, 11^a^      03^a^, 050101    0401, 0402
  U251          41291-D   CNS CA           030101           0201             0402
  COLO 205      41299-D   Colon CA         040101, 130101   0603             0401
  HCC-2998      41300-D   Colon CA         11^a^, 16^a^     030101, 050201   0401
  HCT-116       41301-D   Colon CA         N.R.             02new, 03new     030101, 0402
  HCT-15        41302-D   Colon CA         03^a^, 14^a^     02^a^, 050301    010101, 0401
  HT29          41303-D   Colon CA         0402, 0701       02^a^, 0302      0401
  KM12          41304-D   Colon CA         040101           0302             1301
  SW-620        41305-D   Colon CA         0103, 130101     050101, 0603     010101, 0401
  MOLT 4        41281-D   Leukemia, ALL    07new, 12new     0202, 030101     20102
  CCRF-CEM      41282-D   Leukemia, ALL    030101, 0701     0201, 0202       0401, 1301
  HL-60         41284-D   Leukemia, APL    N.R.             030302           0401, 1301
  K-562         41280-D   Leukemia, CML    03^a^, 04^a^     0201, 0302       0401, 0402
  SR            41285-D   Leukemia, LCIL   01^a^, 160101    050101, 050201   0401
  LOX IMVI      41315-D   Melanoma         0701, 150101     0202, 0602       0401, 110101
  M 14          41316-D   Melanoma         040501, 130101   0302, 0603       1301, 1901
  SK-MEL-2      41317-D   Melanoma         0402, 130101     030101, 0603     020102, 0401
  SK-MEL-5      41319-D   Melanoma         040101, 130101   0302, 0603       030101, 1601
  SK-MEL-28     41318-D   Melanoma         0404             0302             030101
  UACC-62       41321-D   Melanoma         12^a^, 130101    030101, 0603     0401, 1401
  UACC-257      41320-D   Melanoma         040101           030101, 0302     0401
  RPMI-8226     41283-D   MM               030101, 0701     0201, 0202       010102, 1301
  A549/ATCC     41306-D   NSCLC            0701, 110401     0202, 030101     N.R.
  EKVX          41307-D   NSCLC            150101           0602             0401
  HOP-62        41308-D   NSCLC            13^a^, 15^a^     06^a^, 06^a^     0402
  HOP-92        41309-D   NSCLC            01^a^, 150101    050101, 0602     0401, 0402
  NCI-H23       41312-D   NSCLC            130101           0603             1901
  NCI-H226      41311-D   NSCLC            150101, 160101   050201, 0602     020102, 0401
  NCI-H322M     41310-D   NSCLC            0701             0202             0401
  NCI-H460      41313-D   NSCLC            01^a^, 04^a^     030101, 050101   N.R.
  NCI-H522      41314-D   NSCLC            040101, 150101   03^a^, 0602      0401
  IGROV1        41322-D   Ovarian CA       11^a^, 11^a^     03new            new, 0501
  OVCAR-3       41323-D   Ovarian CA       080101, 080401   0402             020102, 0401
  OVCAR-4       41324-D   Ovarian CA       030101, 040101   0201, 030101     0401, 1301
  OVCAR-5       41325-D   Ovarian CA       030101, 040101   0201, 030101     0401
  OVCAR-8       41326-D   Ovarian CA       0701, 150101     030302, 0602     020102, 1301
  NCI/ADR-RES   41295-D   Ovarian CA       0701, 150101     030302, 0602     020102, 1301
  SK-OV-3       41327-D   Ovarian CA       01^a^, 030101    0201, 050101     020102, 0401
  DU-145        41328-D   Prostate CA      N.R.             030302, 050101   0401
  PC-3          41329-D   Prostate CA      0701, 130101     0202, 0603       0401
  786-O         41330-D   Renal CA         13^a^, 15^a^     06^a^, 06^a^     0402
  A498          41331-D   Renal CA         030101           0201             010101
  ACHN          41332-D   Renal CA         160101           050201           020102
  CAKI-1        41333-D   Renal CA         0701, 110401     0202, 03^a^      020102, 1001
  SN12C         41334-D   Renal CA         040101, 150101   03^a^, 0602      N.R.
  TK-10         41335-D   Renal CA         010201           050101           0402
  UO-31         41336-D   Renal CA         130201, 150101   0602, 0609       0402, 0501
  RXF-393       41337-D   Renal CA         110101, 150101   030101, 0602     010101, 0401

Sequence-based typing for the HLA class II loci are reported with the highest degree of resolution. Non-resolved ambiguities are reported as two digit denominations with a superscript ^a^as previously described \[43\]. HLA typings divergent from those originally described in the ATCC database are reported in red. ID\# refers to the HLA laboratory reference number. New alleles are indicated by the suffix new following the allele. N.R. = Ambiguity not resolved at the lower level of resolution.

Overall, there was no evidence of contamination among the cell lines tested with clean homozygous or heterozygous combinations observed in all loci analyzed. SBT of HLA class I and HLA class II loci are reported in Table [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"} respectively. Information about the HLA typing of the cell lines is also available through the Molecular Targets URL: <http://dtp.nci.nih.gov/mtargets/mt_index.html>. Approximately 17% of the cell lines (10 out of 58 including: T47D, SNB-19, U251, KM12, RPMI-8226, EKVX, NCI-H23, NCI-H322M, A498, ACHN and TK-10) exhibited a pseudo-homozygous pattern suggestive of complete loss of heterozygosity encompassing the HLA class I and HLA class II regions. This frequency is close to the loss of haplotype that we originally described for melanoma cell lines generated at the National Cancer Institute (Bethesda, MD) \[[@B38],[@B39]\] and subsequently observed in other cancers \[[@B40],[@B41]\]. We conclude that this is an unlikely representative of patients\' homozygosity because complete HLA class I and II homozygosity is exceedingly rare in the population at large. To corroborate this statement, we analyzed 554 genomic DNA specimens from normal donors recently typed with the same technology in our laboratory. Genomic DNA for the normal donors was obtained from whole blood samples. Only 5 individuals were found to be truly homozygous for all HLA class I and class II loci for a frequency of 0.9%.

Overall, discrepancies between ATCC typings and the present typing or the unbalanced frequency of homozygosity could be related to accumulated genetic alterations between the cell lines since the time of their original expansion from the patient and should not be surprising.

A particular case was represented by the NCI/ADR-RES cell line which was previously believed to be an adriamycin derivative of the breast cancer cell line MCF-7. Subsequently, it was discovered not to be related to MCF-7, but it\'s derivation was unclear \[[@B42]\]. Karyotyping analysis suggested it was related to the ovarian cell line OVCAR-8. Subsequent DNA fingerprinting confirmed that both cell lines were generated from the same individual. HLA genotyping confirms this since the cell lines are indeed identical.

To avoid possible misinterpretations, a large number of alleles are not presented here with their definitive nomenclature but rather at a two digits level of resolution because some of the ambiguities could not be completely resolved by SBT as previously described \[[@B43]\]. However, more detailed information about individual cell lines can be obtained by contacting Sharon Adams directly at the HLA laboratory, Department of Transfusion Medicine, Bethesda, MD. As previously described \[[@B43]\], it is possible to resolve most of these ambiguities using various methods including sequence-specific primer PCR or pyro-sequencing \[[@B44]\]. If necessary in the future, the NIH HLA laboratory may assist in further characterization of individual HLA alleles. Another caveat is that the identification of HLA alleles at the genomic level does not necessarily correspond to surface expression of their protein products since various abnormalities in transcription, translation and assembling could influence the surface expression of HLA molecules \[[@B39],[@B45],[@B46]\].

Finally, several new alleles were identified (referred to in the tables as new, for which a nomenclature is pending; in detail KM12 HLA-A\*02new = Genebank Accession \# AY918166; SN12C HLA-A\*24new = \# AY918167; CAKI-1 HLA-Cw04new = \# AY918170). Information regarding the sequence of these alleles could be obtained by directly contacting the HLA laboratory, Department of Transfusion Medicine, Bethesda, MD.

Materials and Methods
=====================

Cell Lines
----------

Genomic DNA from the NCI-60 cell line anticancer drug discovery panel was obtained from SH of the National Cancer Institute Developmental Therapeutics Program (Bethesda, MD). Cells were grown in RPMI 1640 supplemented with 10% fetal bovine serum and 5 mM L-glutamine.

DNA Isolation
-------------

Genomic DNA was isolated from peripheral blood using the Gentra PUREGENE isolation kit (Gentra Systems, Minneapolis, MN, USA). The DNA was re-suspended in Tris HCl buffer (pH 8.5) and the concentration was measured using a Pharmacia Gene Quant II Spectrophotometer. The DNA was then stored at -70°C until testing.

Sequence-Based Typing (SBT)
---------------------------

HLA class I loci sequence-based typing (SBT) was performed as previously described (\[[@B43]\]. The primary PCR amplification reaction produced a 1.5 kb amplicon encompassing exon 1 through intron 3 of the HLA class I locus. All reagents necessary for primary amplification and sequencing were included in the HLA-A, HLA-B and HLA-C alleleSEQR Sequenced Based Typing Kits (Atria Genetics, Hayward, CA, U.S.A.). The primary amplification PCR products were purified from excess primers, dNTPs and genomic DNA using ExoSAP-IT (American Life Science, Cleveland, OH, U.S.A.). Each template was sequenced in the forward and reverse sequence orientation for exon 2 and exon 3 according to protocols supplied with the SBT kits. Excess dye terminators were removed from the sequencing products utilizing an ethanol precipitation method with absolute ethanol. The reaction products were reconstituted with 15 μl of Hi-Di™ Formamide (PE Applied Biosystems / Perkin-Elmer, Foster City, CA, U.S.A.) and analyzed on the ABI Prism\* 3700 DNA Analyzer with Dye Set file: Z and mobility file: DT3700POP6 \[ET\].
